Bausch + Lomb Corporation Common Shares (NY:BLCO)

17.09 -0.25 (-1.41%)

Delayed Quote Updated: 11:15 AM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Bausch + Lomb (BLCO) Stock Is Up, What You Need To Know

August 22, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 3.1% in the afternoon session after comments from Federal Reserve Chair Jerome Powell raised investor hopes for future interest rate cuts. The...

Via StockStory

Purple, Bausch + Lomb, Etsy, Intel, and Camping World Shares Are Falling, What You Need To Know

August 21, 2025

A number of stocks fell in the afternoon session after markets continued to decline, as investors grew cautious ahead of a key speech by Federal Reserve Chair Jerome Powell. The move came as U.S....

Via StockStory

Topics Economy Stocks

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

Examining the Future: Bausch & Lomb's Earnings Outlook ↗

July 29, 2025

Via Benzinga

Medical Devices & Supplies - Specialty Stocks Q2 Highlights: Bausch + Lomb (NYSE:BLCO)

August 20, 2025

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Bausch + Lomb...

Via StockStory

Bausch + Lomb Announces Board Changes

August 18, 2025

From Bausch + Lomb Corporation

Via Business Wire

1 Safe-and-Steady Stock with Competitive Advantages and 2 That Underwhelm

August 15, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Bausch + Lomb to Participate in Upcoming Investor Conferences

August 14, 2025

From Bausch + Lomb Corporation

Via Business Wire

Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Economy Lawsuit

BLCO Q2 Deep Dive: Product Launches Offset Margin Pressures, Management Highlights Pipeline Investments

August 12, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q2 CY2025, with sales up 5.1% year on year to $1.28 billion. The company’s full-year revenue guidance of $5.1 billion...

Via StockStory

1 Stock Under $50 to Target This Week and 2 We Ignore

August 07, 2025

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Via StockStory

3 Small-Cap Stocks with Warning Signs

August 06, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Bausch Lomb (BLCO) Q2 Revenue Rises 5% ↗

July 30, 2025

Via The Motley Fool

Why Bausch + Lomb (BLCO) Stock Is Down Today

July 30, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 3.1% in the morning session after the company reported mixed second-quarter 2025 financial results where a decline in profitability overshadowed...

Via StockStory

Topics Artificial Intelligence Initial Public Offering

Bausch + Lomb’s (NYSE:BLCO) Q2 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations

July 30, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 5.1% year on year to $1.28 billion. The company’s full-year revenue guidance...

Via StockStory

Bausch + Lomb Announces Second-Quarter 2025 Results

July 30, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout ↗

July 29, 2025

Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via Phase 3 trials.

Via Benzinga

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

July 29, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb (BLCO) Q2 Earnings Report Preview: What To Look For

July 28, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before market hours. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity

July 22, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(NASDAQ:TEM) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Medical Devices & Supplies - Specialty Stocks Q1 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers

July 20, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Bausch + Lomb (NYSE:BLCO) and its peers.

Via StockStory

Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie ↗

July 18, 2025

This week's M&A news includes strategic pivots and stumbles galore, with updates from WK Kellogg, Matador Restaurant and Windsurf.

Via Benzinga

Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye

July 01, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13

June 30, 2025

From Bausch + Lomb Corporation

Via Business Wire

BAUSCH & LOMB ALERT: Bragar Eagel & Squire, P.C. is Investigating Bausch + Lomb Corporation on Behalf of Bausch & Lomb Stockholders and Encourages Investors to Contact the Firm

June 26, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility

June 26, 2025

From Bausch + Lomb Corporation

Via Business Wire

Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

June 24, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

Bausch + Lomb Corporation (BLCO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

June 23, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

June 20, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

June 18, 2025

From Bausch + Lomb Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.